

Maria R Baer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6940652/publications.pdf>

Version: 2024-02-01

142
papers

7,925
citations

94433

37
h-index

49909

87
g-index

143
all docs

143
docs citations

143
times ranked

8446
citing authors

#	ARTICLE	IF	CITATIONS
1	Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML. <i>New England Journal of Medicine</i> , 2019, 381, 1728-1740.	27.0	796
2	<i>IDH1</i> and <i>IDH2</i> Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 2348-2355.	1.6	699
3	Selective inhibition of <i>FLT3</i> by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1/2 study. <i>Lancet Oncology</i> , The, 2017, 18, 1061-1075.	10.7	402
4	Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2012, 30, 4515-4523.	1.6	363
5	Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with <i>FLT3</i> mutant AML in first relapse. <i>Blood</i> , 2011, 117, 3294-3301.	1.4	353
6	Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. <i>Blood</i> , 2002, 100, 1224-1232.	1.4	335
7	Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 3842-3848.	1.6	321
8	Favorable Prognostic Impact of <i>NPM1</i> Mutations in Older Patients With Cytogenetically Normal De Novo Acute Myeloid Leukemia and Associated Gene- and MicroRNA-Expression Signatures: A Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 596-604.	1.6	305
9	Patients With t(8;21)(q22;q22) and Acute Myeloid Leukemia Have Superior Failure-Free and Overall Survival When Repetitive Cycles of High-Dose Cytarabine Are Administered. <i>Journal of Clinical Oncology</i> , 1999, 17, 3767-3775.	1.6	290
10	Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. <i>Blood</i> , 2006, 108, 63-73.	1.4	285
11	Age-Related Prognostic Impact of Different Types of <i>DNMT3A</i> Mutations in Adults With Primary Cytogenetically Normal Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2012, 30, 742-750.	1.6	244
12	<i>FLT3</i> Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 991-1001.	4.1	223
13	Drug resistance: Still a daunting challenge to the successful treatment of AML. <i>Drug Resistance Updates</i> , 2012, 15, 62-69.	14.4	218
14	<i>FLT3</i> internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. <i>Blood</i> , 2010, 116, 3622-3626.	1.4	201
15	Outcome of older patients with acute myeloid leukemia. <i>Cancer</i> , 2013, 119, 2720-2727.	4.1	175
16	Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents – A Potential Therapy for Cancer. <i>Cancer Cell</i> , 2016, 30, 637-650.	16.8	151
17	Comparison of Reduced-Intensity Hematopoietic Cell Transplantation with Chemotherapy in Patients Age 60-70 Years with Acute Myelogenous Leukemia in First Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1796-1803.	2.0	123
18	Outcome of Induction and Postremission Therapy in Younger Adults With Acute Myeloid Leukemia With Normal Karyotype: A Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 482-493.	1.6	119

#	ARTICLE	IF	CITATIONS
19	Low-Dose Interleukin-2 Immunotherapy Does Not Improve Outcome of Patients Age 60 Years and Older With Acute Myeloid Leukemia in First Complete Remission: Cancer and Leukemia Group B Study 9720. <i>Journal of Clinical Oncology</i> , 2008, 26, 4934-4939.	1.6	114
20	P-glycoprotein inhibition using valsopodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. <i>Blood</i> , 2010, 116, 1413-1421.	1.4	113
21	Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. <i>Blood</i> , 2002, 100, 1224-32.	1.4	105
22	Neutropenia Associated With T-Cell Large Granular Lymphocyte Leukemia: Long-Term Response to Cyclosporine Therapy Despite Persistence of Abnormal Cells. <i>Blood</i> , 1998, 91, 3372-3378.	1.4	101
23	Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia. <i>Blood</i> , 2004, 103, 4036-4042.	1.4	96
24	KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. <i>Blood</i> , 2021, 138, 11-22.	1.4	90
25	Pim-1 Kinase Protects P-Glycoprotein from Degradation and Enables Its Glycosylation and Cell Surface Expression. <i>Molecular Pharmacology</i> , 2010, 78, 310-318.	2.3	85
26	Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission. <i>Blood Advances</i> , 2018, 2, 1645-1650.	5.2	85
27	The Novel BCR-ABL and FLT3 Inhibitor Ponatinib Is a Potent Inhibitor of the MDR-Associated ATP-Binding Cassette Transporter ABCG2. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 2033-2044.	4.1	81
28	Flow cytometric analysis of breast cancer resistance protein expression and function. <i>Cytometry</i> , 2002, 48, 59-65.	1.8	75
29	Pim-1 Kinase Phosphorylates and Stabilizes 130 kDa FLT3 and Promotes Aberrant STAT5 Signaling in Acute Myeloid Leukemia with FLT3 Internal Tandem Duplication. <i>PLoS ONE</i> , 2013, 8, e74653.	2.5	59
30	A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. <i>Blood Advances</i> , 2017, 1, 331-340.	5.2	57
31	A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2017, 23, 697-706.	7.0	56
32	c-MYC Generates Repair Errors via Increased Transcription of Alternative-NHEJ Factors, LIG3 and PARP1, in Tyrosine Kinase-Activated Leukemias. <i>Molecular Cancer Research</i> , 2015, 13, 699-712.	3.4	55
33	Interferon- γ -associated focal segmental glomerulosclerosis with massive proteinuria in patients with chronic myeloid leukemia following high dose chemotherapy. <i>Cancer</i> , 1998, 83, 1938-1946.	4.1	45
34	Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy. <i>Leukemia and Lymphoma</i> , 2014, 55, 1533-1537.	1.3	45
35	GAS6 expression identifies high-risk adult AML patients: potential implications for therapy. <i>Leukemia</i> , 2014, 28, 1252-1258.	7.2	45
36	SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2022, 40, 1574-1582.	1.6	44

#	ARTICLE	IF	CITATIONS
37	Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study. <i>Blood</i> , 2020, 136, 55-57.	1.4	40
38	Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420. <i>Clinical Cancer Research</i> , 2002, 8, 2812-9.	7.0	40
39	Disparities in black and white patients with multiple myeloma referred for autologous hematopoietic transplantation: A single center study. <i>Cancer</i> , 2015, 121, 1064-1070.	4.1	37
40	Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation. <i>Clinical Cancer Research</i> , 2018, 24, 234-247.	7.0	34
41	Racial differences in presentation, referral and treatment patterns and survival in adult patients with acute myeloid leukemia: A single-institution experience. <i>Leukemia Research</i> , 2012, 36, 140-145.	0.8	33
42	Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on <i>MIR300</i> Antiproliferative and PP2A-Activating Functions. <i>Blood Cancer Discovery</i> , 2020, 1, 48-67.	5.0	30
43	The FLT3 Inhibitor Quizartinib Inhibits ABCG2 at Pharmacologically Relevant Concentrations, with Implications for Both Chemosensitization and Adverse Drug Interactions. <i>PLoS ONE</i> , 2013, 8, e71266.	2.5	28
44	Subdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy. <i>Leukemia and Lymphoma</i> , 2011, 52, 1211-1214.	1.3	27
45	Ponatinib enhances anticancer drug sensitivity in MRP7-overexpressing cells. <i>Oncology Reports</i> , 2014, 31, 1605-1612.	2.6	26
46	Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia. <i>Blood</i> , 2021, 138, 387-400.	1.4	26
47	Therapeutic targeting of TP53-mutated acute myeloid leukemia by inhibiting HIF-1 α with echinomycin. <i>Oncogene</i> , 2020, 39, 3015-3027.	5.9	25
48	Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8. <i>Leukemia</i> , 2014, 28, 1754-1758.	7.2	24
49	Therapy-related myelodysplastic syndrome and acute myeloid leukemia following treatment of acute myeloid leukemia: Possible role of cytarabine. <i>Leukemia Research</i> , 2008, 32, 1043-1048.	0.8	22
50	The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations. <i>Investigational New Drugs</i> , 2015, 33, 300-309.	2.6	22
51	Normal full-term pregnancy in a patient with chronic myelogenous leukemia treated with α -interferon. <i>American Journal of Hematology</i> , 1991, 37, 66-66.	4.1	21
52	Use of the APACHE II score to assess impact of therapeutic plasma exchange for critically ill patients with hypertriglyceride-induced pancreatitis. <i>Transfusion and Apheresis Science</i> , 2017, 56, 123-126.	1.0	20
53	Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study. <i>Journal of Hematology and Oncology</i> , 2018, 11, 101.	17.0	20
54	Treatment of CD19 α C β -positive mixed phenotype acute leukemia with blinatumomab. <i>American Journal of Hematology</i> , 2019, 94, E7-E8.	4.1	19

#	ARTICLE	IF	CITATIONS
55	Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine. <i>Leukemia and Lymphoma</i> , 2015, 56, 1718-1722.	1.3	18
56	A Phase II Trial Of Epigenetic Modulators Vorinostat In Combination With Azacitidine (azaC) In Patients With The Myelodysplastic Syndrome (MDS): Initial Results Of Study 6898 Of The New York Cancer Consortium. <i>Blood</i> , 2013, 122, 386-386.	1.4	18
57	Optimizing pegylated asparaginase use: An institutional guideline for dosing, monitoring, and management. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 74-92.	0.9	17
58	Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress. <i>Oncotarget</i> , 2016, 7, 48280-48295.	1.8	16
59	Phase I Clinical Trial of DNA Methyltransferase Inhibitor Decitabine and PARP Inhibitor Talazoparib Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2022, 28, 1313-1322.	7.0	16
60	Novel Agents for the Treatment of Acute Myeloid Leukemia in the Older Patient. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 331-335.	4.9	15
61	Relapsed Philadelphia Chromosome-Positive Pre-B-ALL after CD19-Directed CAR-T Cell Therapy Successfully Treated with Combination of Blinatumomab and Ponatinib. <i>Acta Haematologica</i> , 2019, 141, 107-110.	1.4	14
62	Decreased Bleeding Incidence with Direct Oral Anticoagulants Compared to Vitamin K Antagonist and Low-Molecular-Weight Heparin in Patients with Sickle Cell Disease and Venous Thromboembolism. <i>Acta Haematologica</i> , 2019, 142, 233-238.	1.4	14
63	Partnering with PARP inhibitors in acute myeloid leukemia with FLT3-ITD. <i>Cancer Letters</i> , 2019, 454, 171-178.	7.2	14
64	Isochromosome 1q in a myelodysplastic syndrome after treatment for acute promyelocytic leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2006, 167, 155-160.	1.0	13
65	Long-term safety and efficacy of cyclosporin A therapy for T-cell large granular lymphocyte leukemia. <i>Leukemia and Lymphoma</i> , 2010, 51, 338-341.	1.3	12
66	Tertiary center referral patterns for patients with myelodysplastic syndrome are indicative of age and race disparities: a single-institution experience. <i>Leukemia and Lymphoma</i> , 2013, 54, 304-309.	1.3	12
67	Equipotent doses of daunorubicin and idarubicin for AML: a meta-analysis of clinical trials versus in vitro estimation. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 1105-1112.	2.3	12
68	Overall Survival and Subgroup Analysis from a Randomized Phase III Study of Intravenous Rigosertib Versus Best Supportive Care (BSC) in Patients (pts) with Higher-Risk Myelodysplastic Syndrome (HR-MDS) after Failure of Hypomethylating Agents (HMAs). <i>Blood</i> , 2014, 124, 163-163.	1.4	12
69	High-dose cytosine arabinoside and idarubicin treatment of chronic myeloid leukemia in myeloid blast crisis. <i>American Journal of Hematology</i> , 2001, 67, 119-124.	4.1	11
70	Exploiting epigenetically mediated changes: Acute myeloid leukemia, leukemia stem cells and the bone marrow microenvironment. <i>Advances in Cancer Research</i> , 2019, 141, 213-253.	5.0	11
71	Uncommon patterns of presentation of leukemia. , 1999, 17, 11-29.		10
72	High frequency of rare structural chromosome abnormalities at relapse of cytogenetically normal acute myeloid leukemia with FLT3 internal tandem duplication. <i>Cancer Genetics</i> , 2014, 207, 467-473.	0.4	10

#	ARTICLE	IF	CITATIONS
73	PP2A-activating Drugs Enhance FLT3 Inhibitor Efficacy through AKT Inhibitionâ€œDependent GSK-3Î²â€œMediated c-Myc and Pim-1 Proteasomal Degradation. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 676-690.	4.1	10
74	Detection of minimal residual disease in acute myeloid leukemia. <i>Current Oncology Reports</i> , 2002, 4, 398-402.	4.0	9
75	Effects of Toll-like receptor signals in T-cell neoplasms. <i>Future Oncology</i> , 2011, 7, 309-320.	2.4	9
76	Hydroxylated Dimeric Naphthoquinones Increase the Generation of Reactive Oxygen Species, Induce Apoptosis of Acute Myeloid Leukemia Cells and Are Not Substrates of the Multidrug Resistance Proteins ABCB1 and ABCG2. <i>Pharmaceuticals</i> , 2016, 9, 4.	3.8	9
77	Activating STING1-dependent immune signaling in <i>TP53</i> mutant and wild-type acute myeloid leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	7.1	9
78	Is there a role for maintenance therapy in acute myeloid leukaemia?. <i>Best Practice and Research in Clinical Haematology</i> , 2009, 22, 517-521.	1.7	8
79	<i>Scedosporium apiospermum</i> Soft Tissue Infection As the Initial Presentation of Acute Myeloid Leukemia: A Case Report. <i>Journal of Clinical Oncology</i> , 2013, 31, e98-e100.	1.6	8
80	Variations in erythropoiesis-stimulating agent administration in transfusion-dependent myelodysplastic syndromes impact response. <i>Leukemia Research</i> , 2015, 39, 586-591.	0.8	8
81	Cryptic ETV6â€œPDGFRB fusion in a highly complex rearrangement of chromosomes 1, 5, and 12 due to a chromothripsis-like event in a myelodysplastic syndrome/myeloproliferative neoplasm. <i>Leukemia and Lymphoma</i> , 2019, 60, 1304-1307.	1.3	8
82	Precision Medicine Treatment in Older AML: Results of Beat AML Master Trial. <i>Blood</i> , 2019, 134, 175-175.	1.4	8
83	Effect of Erythropoiesis-Stimulating Agent Policy Decisions on Off-Label Use in Myelodysplastic Syndromes. <i>Medicare & Medicaid Research Review</i> , 2014, 4, E1-E16.	1.3	8
84	Acute myeloid leukemia and myelodysplastic syndrome following breast cancer: Increased frequency of other cancers and of cancers in multiple family members. <i>Leukemia Research</i> , 2008, 32, 1820-1823.	0.8	7
85	Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in pregnancy. <i>Journal of Oncology Pharmacy Practice</i> , 2016, 22, 374-377.	0.9	7
86	Thrombotic microangiopathy in the setting of human immunodeficiency virus infection: High incidence of severe thrombocytopenia. <i>Journal of Clinical Apheresis</i> , 2018, 33, 342-348.	1.3	7
87	Peripheral blood blast rate of clearance is an independent predictor of clinical response and outcomes in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2020, 188, 881-887.	2.5	7
88	Favorable outcomes of acute leukemias of ambiguous lineage treated with hyperCVAD: a multi-center retrospective study. <i>Annals of Hematology</i> , 2020, 99, 2119-2124.	1.8	7
89	Black Patients with Acute Myeloid Leukemia (AML) Are Younger and More Commonly Female, but Have a Higher Incidence of Complex Karyotypes When Compared to Whites.. <i>Blood</i> , 2009, 114, 2649-2649.	1.4	7
90	PARP1 PARYlates and stabilizes STAT5 in FLT3-ITD acute myeloid leukemia and other STAT5-activated cancers. <i>Translational Oncology</i> , 2022, 15, 101283.	3.7	7

#	ARTICLE	IF	CITATIONS
91	Novel t(5;11)(q32;q13.4) with NUMA1 - PDGFRB fusion in a myeloid neoplasm with eosinophilia with response to imatinib mesylate. <i>Cancer Genetics</i> , 2017, 212-213, 38-44.	0.4	6
92	High-risk acute promyelocytic leukemia with unusual T/myeloid immunophenotype successfully treated with ATRA and arsenic trioxide-based regimen. <i>Journal of Hematopathology</i> , 2018, 11, 67-74.	0.4	5
93	Frontline Blinatumomab in Older Adults with Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. <i>Pharmaceuticals</i> , 2020, 13, 124.	3.8	5
94	Arsenic trioxide dose capping to decrease toxicity in the treatment of acute promyelocytic leukemia. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 1340-1349.	0.9	5
95	Increased body mass index is a risk factor for acute promyelocytic leukemia. <i>EJHaem</i> , 2021, 2, 33-39.	1.0	5
96	Expression of the Neural Cell Adhesion Molecule CD56 Is Associated With Short Remission Duration and Survival in Acute Myeloid Leukemia With t(8; 21)(q22; q22). <i>Blood</i> , 1997, 90, 1643-1648.	1.4	5
97	Patient Cost Sharing and Receipt of Erythropoiesis-Stimulating Agents Through Medicare Part D. <i>Journal of Oncology Practice</i> , 2015, 11, e190-e198.	2.5	4
98	Sickle Cell Disease Complicated by Iron Overload: An Under-Recognized Risk Factor for <i>Vibrio vulnificus</i> Infection. <i>Acta Haematologica</i> , 2018, 139, 199-200.	1.4	4
99	Venous thromboembolism incidence and risk factors in adults with acute lymphoblastic leukemia treated with and without pegylated E. coli asparaginase-containing regimens. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 817-826.	2.3	4
100	Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS). <i>Cancer</i> , 2021, 127, 4421-4431.	4.1	4
101	Interferon- γ -associated focal segmental glomerulosclerosis with massive proteinuria in patients with chronic myeloid leukemia following high dose chemotherapy. <i>Cancer</i> , 1998, 83, 1938-1946.	4.1	3
102	Novel BRCA2 c.8434_8435insTT (p. Gly2812Valfs*10) mutation in a family with multiple hematologic malignancies and solid tumors. <i>Leukemia and Lymphoma</i> , 2021, 62, 1275-1277.	1.3	3
103	Enasidenib (ENA) Monotherapy with Addition of Azacitidine in Non-Responders Is Effective in Older Patients with Newly Diagnosed IDH2 Mutated Acute Myeloid Leukemia (AML): A Completed Phase 2/1b Sub-Study of the Beat AML Master Trial. <i>Blood</i> , 2020, 136, 27-30.	1.4	3
104	Initial Results Of a Phase II Trial Of Sorafenib Plus Standard Induction In Older Adults With Mutant FLT3 Acute Myeloid Leukemia (AML) (Alliance trial C11001). <i>Blood</i> , 2013, 122, 2653-2653.	1.4	3
105	High Dose Cytosine Arabinoside, Idarubicin and G-CSF Therapy for De Novo and Secondary Adult Acute Myeloid Leukemia. <i>Leukemia and Lymphoma</i> , 1992, 7, 8-10.	1.3	2
106	T/B and not T/B: High frequency of B-cell dyscrasias in T-LGL leukemia. <i>Leukemia and Lymphoma</i> , 2008, 49, 845-846.	1.3	2
107	Upfront Therapy of Acute Myeloid Leukemia. <i>Current Oncology Reports</i> , 2011, 13, 361-370.	4.0	2
108	FLT3 Inhibitors as Sensitizing Agents for Cancer Chemotherapy. , 2019, , 67-88.		2

#	ARTICLE	IF	CITATIONS
109	Pim kinase inhibitor co-treatment decreases alternative non-homologous end-joining DNA repair and genomic instability induced by topoisomerase 2 inhibitors in cells with FLT3 internal tandem duplication. <i>Oncotarget</i> , 2021, 12, 1763-1779.	1.8	2
110	Dimeric Naphthoquinones: Novel Anti-Leukemic Agents Modulating Cellular Redox Status. <i>Blood</i> , 2013, 122, 1290-1290.	1.4	2
111	An Electronic Teaching Module for Improving Knowledge of Self-Management of Vaso-Occlusive Pain Crises in Patients With Sickle Cell Disease: Pilot Questionnaire Study. <i>JMIR MHealth and UHealth</i> , 2019, 7, e13501.	3.7	2
112	Disseminated histoplasmosis mimicking hematologic malignancy in a patient with human immunodeficiency virus. <i>EJHaem</i> , 2022, 3, 545-546.	1.0	2
113	Aspartate β -Hydroxylase (ASPH) Expression in Acute Myeloid Leukemia: A Potential Novel Therapeutic Target. <i>Frontiers in Oncology</i> , 2021, 11, 783744.	2.8	2
114	Littoral cell angioma: A correctable cause of progressive pancytopenia in a patient with myelodysplastic syndrome. <i>Leukemia Research</i> , 2010, 34, e117-e119.	0.8	1
115	Development of Hypercalcemia in a Patient Receiving Peginterferon alfa-2a Therapy for Polycythemia Vera. <i>Pharmacotherapy</i> , 2016, 36, e54-e57.	2.6	1
116	Characteristics and outcomes of therapy-related myeloid neoplasms after treatment for multiple myeloma. <i>Leukemia and Lymphoma</i> , 2019, 60, 3577-3580.	1.3	1
117	Babesiosis Masquerading as Evans Syndrome. <i>American Journal of Medicine</i> , 2019, 132, e616-e617.	1.5	1
118	Jumping translocations of chromosome 1q occurring by a multi-stage process in an acute myeloid leukemia progressed from myelodysplastic syndrome with a TET2 mutation. <i>Molecular Cytogenetics</i> , 2019, 12, 47.	0.9	1
119	An unusual presentation of paroxysmal nocturnal haemoglobinuria. <i>British Journal of Haematology</i> , 2020, 188, 347-347.	2.5	1
120	FLT3-ITD Allelic Burden and Acute Promyelocytic Leukemia Risk Stratification. <i>Biology</i> , 2021, 10, 243.	2.8	1
121	Primary myelofibrosis in a patient with sickle cell disease. <i>American Journal of Hematology</i> , 2022, 97, 160-161.	4.1	1
122	A 14q32.31 Genomic-Imprinted DLK1-DIO3 microrna promotes Leukemogenesis By Inducing Stem Cell Quiescence and Inhibiting NK Cell Anti-Cancer Immunity. <i>Blood</i> , 2019, 134, 4141-4141.	1.4	1
123	Newly Diagnosed AML Patient Samples Demonstrate High Degree of Concordance in Identification of Pathogenic Mutations By Next Generation Sequencing (NGS) Performed at Enrolling Institutions Compared to Central Laboratory Results in the Beat AML Master Trial. <i>Blood</i> , 2019, 134, 2145-2145.	1.4	1
124	The mTOR Inhibitor Rapamycin Inhibits Drug Transport in Multidrug Resistant Cell Lines and in Acute Myeloid Leukemia (AML) Cells.. <i>Blood</i> , 2005, 106, 1512-1512.	1.4	1
125	Efficacy of Decitabine in the Treatment of Patients with Chronic Myelomonocytic Leukemia (CMML).. <i>Blood</i> , 2006, 108, 2676-2676.	1.4	1
126	Rare Leukemias. , 2006, , 543-554.		0

#	ARTICLE	IF	CITATIONS
127	Rare hemoglobinopathy presenting as progressive dyspnea: Response to letter. American Journal of Hematology, 2012, 87, 132-132.	4.1	0
128	Acute Onset Unilateral Proptosis. American Journal of Medicine, 2018, 131, e337-e338.	1.5	0
129	Clustered incidence of adult acute promyelocytic leukemia in the vicinity of Baltimore. Leukemia and Lymphoma, 2020, 61, 2743-2747.	1.3	0
130	Effect of Bone Marrow Hypoplasia Secondary to Reinduction Therapy for Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) on Outcomes after Blood and Marrow Transplantation (BMT).. Blood, 2006, 108, 3033-3033.	1.4	0
131	C-MYC and C-MYC-Regulated Micrnas Increase The Activity Of The Error-Prone ALT NHEJ Pathway Through Upregulation Of LIG3 and PARP1 In Tyrosine Kinase-Activated Leukemias. Blood, 2013, 122, 809-809.	1.4	0
132	Differential Clinical Impact Of Gene Mutations and Their Combinations In Primary Cytogenetically Normal Acute Myeloid Leukemia (CN-AML). Blood, 2013, 122, 2540-2540.	1.4	0
133	Demethylating Agents Reprogram Myelodysplastic Syndrome and Leukemia Cells, Sensitizing Them To Poly-(ADP)-Ribose Polymerase Inhibitors. Blood, 2013, 122, 3778-3778.	1.4	0
134	Relationship of Bone Marrow Blast (BMBl) Response to Overall Survival (OS) in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Treated with Rigosertib after Failure of Hypomethylating Agents (HMAs). Blood, 2014, 124, 3259-3259.	1.4	0
135	MiR-300 Acts As a Tumor Suppressor in Ph+ Progenitors By Modulating the JAK2-SET/PP2A/β2-Catenin Interplay. Blood, 2014, 124, 4529-4529.	1.4	0
136	Racial Differences in Molecular Cytogenetic Abnormalities in Black and White Patients with Multiple Myeloma (MM): A Single-Center Experience. Blood, 2015, 126, 1767-1767.	1.4	0
137	DNA Methyltransferase Inhibitors Promote Homologous Recombination Deficiency through Induction of Immune Signaling, Sensitizing Acute Myeloid Leukemia Cells to PARP Inhibitors. Blood, 2019, 134, 3763-3763.	1.4	0
138	Moxifloxacin-Induced Thrombocytopenia Mediated by Moxifloxacin-Dependent IgM and IgG Antiplatelet Antibodies: A Case Report. Cureus, 2020, 12, e10507.	0.5	0
139	Pim Kinase Inhibitor Enhances FLT3 Inhibitor Efficacy through GSK-3β Activation and GSK-3β-Mediated Proteasomal Degradation of c-Myc. Blood, 2021, 138, 1163-1163.	1.4	0
140	Impact of Cardiovascular Disease on Clinical Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. Blood, 2020, 136, 37-38.	1.4	0
141	Hypomethylating Agent Therapy for Chronic Myelomonocytic Leukemia Does Not Impact Acute Myeloid Leukemia Transformation or Survival. Blood, 2020, 136, 6-7.	1.4	0
142	Gastrointestinal Vasooclusive Crisis in a Woman with Hemoglobin SC Disease. American Journal of Medicine, 2022, , .	1.5	0